GNPX News and Press, Genprex Inc. From 07/28/23

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its previously announced registered direct offering. The offering was comprised of 7,425,744 shares of the company's common stock as we...

Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas , July 21, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene thera...

2023-07-19 11:47:18 ET Genprex ( NASDAQ: GNPX ) said Wednesday that it priced a registered direct offering to raise $7.5 million. The company will issue and sell 7,425,744 shares and warrants to purchase up to 7,425,744 shares at a combined offering price of $1.01 p...

2023-07-19 10:22:17 ET Gainers: Panbela Therapeutics ( PBLA ) +36% . 60 Degrees Pharmaceuticals ( SXTP ) +20% . CareMax ( CMAX ) +20% . Biodexa Pharmaceuticals ( BDRX ) +13% . bluebird bio ( BLUE ) +13% . Losers: Amar...

2023-07-19 08:30:52 ET Aqua Metals ( AQMS ) -27% after disclosing stock offering . Amarin Corporation ( AMRN ) -20% on plan to undergo restructuring . Biophytis ( BPTS ) -18% on $3.8M offering . Genprex ( GNPX ) -14% on $7.5 Millio...

Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas , July 19, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has signed an exclusive license agreement with the University of Pittsburgh. The agreement grants Genprex worldwide, exclusive rights to a patent app...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborat...

AUSTIN, TX / ACCESSWIRE / July 11, 2023 / The U.S. Food and Drug Administration (FDA) recently granted Fast Track Designation (FTD) for REQORSA® Immunogene Therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA typically awards FTD if it determines that non-...